Junji Kojima

New drugs for the treatment of hypercholesterolaemia

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

Aptamers as therapeutics

Natural products to drugs: natural product-derived compounds in clinical trials

Mechanisms of drug combinations: interaction and network perspectives

Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor

Allometric scaling of xenobiotic clearance: Uncertainty versus universality

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Human viral cardiomyopathy

Effect of YM‐53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters

2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

A circadian gene expression atlas in mammals: Implications for biology and medicine

Gene-Targeted Mice Lacking the Trex1 (DNase III) 3′→5′ DNA Exonuclease Develop Inflammatory Myocarditis

Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules

Recurrent left ventricular mural thrombi in a patient with acute myocarditis

Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection

INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL

Lipid-lowering and Antiatherosclerotic Effect of NK-104, a Potent 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, in Watanabe Heritable Hyperlipidemic Rabbits

Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase. (4). Interspecies Variation in Laboratory Animals and Humans.

Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase—Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr 1a/b Gene Disruption on Tissue Distribution in Mice

Studies on the Interaction between Fibrates and Statins Using Human Hepatic Microsomes

Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase

Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs.

Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. I. Studies on interspecies variation in laboratory animals.

Interaction between Several Medicines and Statins

Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase. (5). In Vitro Metabolism and Plasma Protein Binding in Animals and Human.